CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.

ABSTRACT:

Background

Regulatory T cells (T_regs) contribute to an immunosuppressive tumor microenvironment. They play an important role in the establishment and progression of tumors with high T_regs infiltration and present a major obstacle to tumor eradication by immunotherapies. Numerous strategies have been attempted to deplete or block T_regs, although their success has been limited.

Methods

A CD25-targeted, pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) was investigated for its ability to deplete T_regs and induce antitumor immunity. Antitumor activity of CD25-ADC either alone or in combination with an anti-programmed cell death protein 1 (PD-1) antibody was evaluated in CD25-negative syngeneic models that exhibit tu

SUBMITTER: Zammarchi F 

PROVIDER: S-EPMC7482493 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature